VPRO Merger 8k VIROPRO INC FILES (8-K) Disclosin
Post# of 72711
Item 1.01 Enty into a material definitive agreement
Viropro and Therapix (formerly Nasvax), an Israeli company trading on the Tel Aviv Stock Exchange , have signed a non-binding letter of intent to merge or otherwise combine the two companies, which would result in Viropro directly or indirectly owning all of the Therapix assets, rights, and liabilities. Therapix is developing an Anti CD 3 immunotherapy technology, which would complement Viropro's present technologies to focus on the treatment of diabetes." The transaction is subject to several conditions, including completion of due diligence by both companies, execution of necessary documents, approval by the directors and shareholders, and compliance with applicable regulatory agencies governing the respective companies.